Understanding Sjögren Disease: More Than Dry Eyes and Dry Mouth – A Patient Guide
Updated: Oct 5

Dry eyes and dry mouths are among the best-known features of Sjögren disease, but they tell only part of the story. Sjögren is a systemic autoimmune disease that can affect far more than the tear and salivary glands, and no two patients experience it in exactly the same way.
Our understanding of Sjögren disease is also changing rapidly. Even its name has recently changed, and after decades without an approved disease-modifying therapy, several targeted treatments are now showing encouraging results in late-state clinical trials.
What Is Sjögren Disease?
Sjögren (pronounced "SHOW-grin") is a heterogeneous systemic autoimmune disease. That means the immune system which normally fights infections and abnormal cells, mistakenly attacks the body's own tissues. In Sjögren disease, the main targets are the glands that make moisture – chiefly the tear glands and the saliva glands.
The result is the hallmark pair of symptoms: dry eyes and dry mouths. But here is the part many people don't realize: Sjögren disease is far more than dryness, it can extend to systemic organ involvement, fatigue, pain, and long-term complications which vary substantially from one person to another – and the treatment is finally beginning to reflect that complexity.
Sjögren disease is a relatively common systemic autoimmune rheumatic disease, although estimates of its prevalence vary depending on the population and diagnostic criteria used.
A Little History: Who Was Sjögren?
The disease is named for Dr. Henrik Sjögren, a Swedish eye doctor. in 1933, he published a detailed study of 19 patients with a severe dry eye condition he called "keratoconjunctivitis sicca". He noticed these patients were mostly women, had both dry eyes and dry mouths, and often had artiritis too. Others had glimpsed the condition before him, but his thorough, lifelong study earned the disease his name. Nearly a century later, we understand it as a complex, whole-body autoimmune disease – a huge leap from "just dry eyes".
Why the Name Recently Changed: "Disease" not "Syndrome"
For decades this condition was called Sjögren's Syndrome. In 2023, an international group of experts and – importantly – patients agreed to officially change the name to Sjögren disease (abbreviated SjD). This came out of what is called the 2023 International Rome Consensus.
Why the change? Two main reasons:
A "syndrome" versus a "disease". A syndrome describes a recognizable group of signs and symptoms that may not necessarily reflect a single defined disease process. Sjögren, however, is now understood as a distinct autoimmune disease with characteristic immune abnormalities, glandular pathology, and patterns of systemic involvement.
Respect and recognition for patients. Many patients felt the word "syndrome" made their condition sound like a vague bundle of "nuisance" complaints, when in fact Sjögren can cause serious problems. The new name helps convey that this is a real, significant illness – which also helps drive research funding and awareness.
One more update: doctors used to split cases into "primary" (Sjögren alone) and "secondary" (Sjögren alongside another autoimmune disease like lupus or rheumatoid arthritis). The new guidance replaces "secondary" with the word "associated". So instead of "secondary Sjögren's", you may now hear "Sjögren disease associated with lupus", for example.
Beyond Dryness: What Else Sjögren Disease Can Affect
In about 30-40% of patients, Sjögren Disease reaches beyond the tear and salivary glands and affects other parts of the body. This is called systemic or extraglandular involvement, and it can include:
Joints – joints pain and stiffness are common, and some patients develop inflammatory arthritis and joint swelling.
Muscles – muscle aches can occur, while true inflammatory muscle disease (myositis) is less common but is an important potential manifestation.
Skin and blood vessels – rashes, Raynaud's phenomenon (fingers that change color with cold or stress), and inflammation of small blood vessels (vasculitis) can occur. Some patients develop abnormal immune proteins called cryoglobulins, which can be associated with vasculitis and other systemic complications.
Lungs – Sjögren disease can affect both the airways and lung tissue, including interstitial lung disease.
Nervous system – both the central and peripheral nervous system can be affected, and Sjögren disease can overlap with neuromyelitis optica and small fiber neuropathy.
Kidneys – inflammation can affect the kidney tubules and intergere with the body's ability to maintain the proper balance of acids and electrolytes. Other forms of kidney involvement are less common
Liver – Sjögren disease can coexist with autoimmune liver diseases, particularly primary biliary cholangitis and, less commonly, autoimmune hepatitis.
An Important Point About Lymphoma
Another reason your rheumatologist monitors Sjögren disease carefully over the long term is a small but real increased risk of a type of blood cancer called lymphoma. However, the absolute risk remains relatively low for most pateints, and the risk is not the same for everyone. Certain clinical and laboratory features can identify patients who warrant closer monitoring. These include persistent swelling of the salivary glands, enlarged lymph nodes, vasculitis, the presence of cryoglobulins, low complement levels, and certain other abnormalities on blood testing.
New or persistent systemic symptoms such as unexplained weight loss, drenching night sweats or persistent fevers should also be discussed with your physician.
Most people with Sjögren disease will never develop lymphoma, but recognizing these fatures help rheumatologists determine who may benefit from closer observation.
A Special Consideration: Pregnancy
Sjögren disease disproportionately affects women, including women of childbearing age. Women with Sjögren disease can have successful pregnancies. However, pregnancy deserves some additional planning, particularly for patients with anti-SSA/Ro or anti-SSB/La antibodies. These antibodies can cross the placenta and, in a small percentage of pregnancies, affect the developing baby. The most important complication is congenital heart block, a rare but a potentially serious abnormality of the baby's heart rhythm. The antibodies can also cause other features of neonatal lupus, such as a temporal skin rash or blood-count abnormalities.
For this reason, women with Sjögren disease who are pregnant or planning pregnancy should discuss their medications and antibody status with their rheumatologist and obsteric team. Depending on the individual situation, additional monitoring during pregnancy may be recommended.
How Sjögren Disease Is Diagnosed
Dry eyes and dry mouth are extremely common and usually are not caused by autoimmune disease, so diagnosing Sjögren disease takes more than symptoms alone. Also, there is no single blood test that diagnoses Sjögren disease, and anti-SSA/SSB negativity does not automatically exclude Sjögren disease. Diagnosis is based on the overall clinical picture together with objective evidence of autoimmune and gland dysfunction. Rheumatologists often use the 2016 ACR/EULAR classification criteria as an important framework, but classification criteria were developed primarily for research and do not replace individualized clinical judgment.
How Sjögren Disease Is Treated Today
Right now, the foundation of treatment is relieving symptoms and protecting the glands and organs. There is no medication yet that is FDA-approved specifically to cure or reverse Sjögren disease – but as you'll see below, that may be changing soon.
For dry eyes
Artificial tears, lubricating gels, and ointments
Prescription immunomodulatory or immunosuppressant eye drops (such as lifitegrast [Xiidra] or cycloporine [Restasis])
Punctal plugs – tiny plugs that keep your natural tears from draining away too quickly
For dry mouth
Sipping water, sugar-free gum or lozenges, and saliva substitutes
Prescription medicine (pilocarpine or cevimeline) that stimulate saliva flow
Diligent dental care – dry mouth raises the risk of cavities, so regular dental visits are essential
For extraglandular or systemic involvement
Treatment is individualized according to the type and severity of the manifestation. For example, hydroxychloroquine alone may be sufficient for mild inflammatory arthritis, while refratractory inflammatory arthritis, interstitial lung disease, vasculitis, inflammatory muscle disease, kidney disease, or neurologic involvement may require more intensive immunomodulatory or immunosuppressive treatment. Importantly, tratment is not determined by the organ involvement alone: the severity and pattern of disease, other medical conditions, and the severity and pattern of disease, other medical conditions, and the individual patient's circumstances all help determine which therapy is most appropriate. Depending on the clinical situation, rheumatologists may use hydroxychloroquine, corticosteroids, methotrexate, leflunomide, azathioprine, mycophenolate mofetil, cyclophosphamide, or rituximab, among other therapies.
New Treatments on the Horizon
For many years, treatment of Sjögren disease has focused largely on relieving dryness and other symptoms and using existing immunosuppressive therapies when systemic disease requires treatment. However, our understanding of the immune pathways involved in Sjögren disease has advanced considerably. B cells, as well as the signals that allow different immune cels to communicate with one another, have become important targets for new therapies.
Here are some of the most promising investigational treatments:
Ianalumab targets the BAFF receptor, an important survical signal for B cells, while also reducing B-cell numbers. Two large phase 3 trials have reported improvement in systemic disease activity in active Sjögren disease, making ianalumab one of the most advanced potential disease-modifying therapies for Sjögren disease.
Dazodalibep targets CD40 ligand, interfering with an important pathway through T cells, B cells, and other immune cells communicate. In 2026, a phase 3 trial in patients with moderate-to-severe systemic Sjögren disease also reported improvement in systemic disease activity. Another phase 3 study is evaluating dazodalibep in patients who have substantial symptoms such as dryness, fatigue, and pain despite relatively low systemic disease activity.
Nipocalimab targets the neonatal Fc receptor (FcRn), a pathway that helps maintain IgG antibodies in the circulation. By blocking this pathway, the tratment lowers circulating IgG, including potentially disease-driving autoantibodies. A randomized phase 2 trial whowed improvement in systemic disease activity, and further investigation is underway.
The bigger picture: treatment is shifting from symptom relief and broad immunosuppression toward targeted therapies designed to interrupt specific immune pathways that drive the disease – and potentially the first-ever FDA-approved disease-modifying drug for Sjögren disease.
Common Questions:
Is Sjögren disease the same as Sjögren's syndrome? Yes – it's the same condition. "Sjögren disease" is simply the updated, officially preferred name as of 2023
Will I definitely get lymphoma? No. The great majority of people with Sjögren disease never develop lymphoma. Regular monitoring is the key.
Is there a cure? Not yet – but for the first time, treatments that target the disease itself are advancing through clinical trials.
This article is for general education and is not a substitute for personalized medical advice. If you have questions about your own symptoms or care, please call our office at (516)-928-6512 to schedule a visit — we're here to help.



Comments